Hillsdale Investment Management Inc. Purchases New Position in Theravance Biopharma, Inc. $TBPH

Hillsdale Investment Management Inc. acquired a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 310,700 shares of the biopharmaceutical company’s stock, valued at approximately $4,536,000. Hillsdale Investment Management Inc. owned approximately 0.62% of Theravance Biopharma at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in TBPH. Baader Bank Aktiengesellschaft purchased a new position in shares of Theravance Biopharma during the third quarter worth about $781,000. Inspire Investing LLC purchased a new stake in shares of Theravance Biopharma during the third quarter worth approximately $1,074,000. Assenagon Asset Management S.A. grew its position in Theravance Biopharma by 1,629.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after buying an additional 390,735 shares during the last quarter. Acadian Asset Management LLC increased its stake in Theravance Biopharma by 76.8% in the 2nd quarter. Acadian Asset Management LLC now owns 308,652 shares of the biopharmaceutical company’s stock valued at $3,401,000 after buying an additional 134,058 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Theravance Biopharma in the 2nd quarter worth $624,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TBPH. Wall Street Zen cut Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. BTIG Research restated a “buy” rating and set a $40.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 3rd. HC Wainwright lifted their price objective on Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Oppenheimer started coverage on Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price objective on the stock. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $27.80.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total transaction of $582,506.25. Following the sale, the senior vice president directly owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. The trade was a 10.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.90% of the company’s stock.

Theravance Biopharma Stock Performance

TBPH stock opened at $19.66 on Monday. The firm has a market cap of $996.17 million, a P/E ratio of 34.49 and a beta of 0.15. The stock has a 50-day simple moving average of $19.28 and a 200-day simple moving average of $16.58. Theravance Biopharma, Inc. has a 1 year low of $7.90 and a 1 year high of $21.03.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.